eligibility_summary
Eligibility: Adults (>18) with biopsy-confirmed primary membranous nephropathy and persistent proteinuria (avg 24‑h urine protein ≥3.5 g, measured twice in 1 week) after ≥3 months of ACE inhibitor or ARB therapy. Exclusions: secondary membranous nephropathy (HBV/HCV, SLE, drugs, malignancy), active infections (HBV, HCV, TB within 1 year, HIV), or any immunodeficiency or prior organ transplantation.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Multicenter study in Chinese primary membranous nephropathy compares rituximab monotherapy vs rituximab plus glucocorticoids, with a parallel real‑world cohort. Drugs: Rituximab—chimeric anti‑CD20 monoclonal antibody (biologic) that depletes B cells via complement‑dependent cytotoxicity/ADCC/apoptosis, Glucocorticoids—systemic steroid immunosuppressants (glucocorticoid‑receptor agonists) that suppress NF‑κB/AP‑1 signaling, cytokines, and antibody production. Targets/pathways: CD20+/CD19+ B cells (reducing anti‑PLA2R autoantibodies), complement‑mediated podocyte injury in glomeruli, biomarkers include CD19+ counts, anti‑PLA2R levels, eGFR. Multi‑omics will map treatment‑responsive immune and renal pathways.